Skip to main content

Inhibitor Therapeutics, Inc. (INTI)

OTCMKTS: INTI · IEX Real-Time Price · USD
0.1700 0.0000 (0.00%)
Oct 22, 2021 9:30 AM EDT - Market closed
Market Cap64.07M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out376.86M
EPS (ttm)0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume0
Open0.1700
Previous Close0.1700
Day's Range0.1700 - 0.1700
52-Week Range0.0300 - 0.3200
Beta-0.42
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About INTI

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed...

IndustryBiotechnology
Founded1992
CEONicholas Virca
Employees1
Stock ExchangeOTCMKTS
Ticker SymbolINTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.